Testing mibavademab for generalized lipodystrophy in adults and children
Treatments studied
Part of Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This trial tests a new drug called mibavademab for people with generalized lipodystrophy, a condition where the body can't store fat properly, leading to problems like diabetes and high triglycerides. It aims to see if the drug safely improves these metabolic issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of generalized lipodystrophy (either from birth or acquired).
- For adults and children age 2 and older: your blood sugar (HbA1c) must be 7% or higher, or your fasting triglycerides (a type of fat) must be 500 mg/dL or higher, or both.
- For children under 12: you need to weigh at least 15 pounds (7 kg), and no specific blood test levels are required.
- You cannot have partial lipodystrophy or type 1 diabetes.
- You cannot have had cancer in the past year or serious heart problems.
- Your kidney function must be at a certain level (estimated by a blood test).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a medication called tirzepatide (Mounjaro) to see if it can help people with a rare fat disorder called familial partial lipodystrophy. The study hopes to improve blood sugar control and lower triglycerides, which are often high in this condition.
This trial tests a new drug called mibavademab for people with severe obesity caused by changes in the leptin (LEP) gene. It aims to see if the drug can help with weight loss in children, teens, and adults who have this rare genetic condition.
This trial tests an open-label study of metreleptin in people with partial lipodystrophy, a condition where fat is lost from some areas of the body. The goal is to see if the drug can help manage related health problems.
This trial tests whether a diabetes medication called a GLP-1 receptor agonist (semaglutide) can help people with Duchenne muscular dystrophy manage weight and reduce metabolic complications like high blood pressure and high cholesterol. The medication may help protect heart and metabolic health in this population.
This trial tests a new injection (BGM1812) for weight loss in people who are overweight or obese. The injection is given under the skin, and the study will see how it works in your body and how safe it is.
This trial studies whether a low-calorie (low energy) diet can improve diabetes control in adults with familial partial lipodystrophy. It likely helps by changing how your body handles blood sugar and fat use, but you must meet specific safety and eligibility checks.
Hear when a new Generalized Lipodystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.